Novartis won the approval in China for its multiple sclerosis drug Gilenya. Officially, only about 30,000 people in China live with multiple sclerosis (compared to 1 million in the US), but the actual number might be a lot higher, as most Chinese aren’t familiar with the disease.
Please follow and like us:
